VAR Varian Medical Systems Inc. featured news, full reports, and detailed charts
Varian Medical Systems Inc. (VAR) Wrap Up:
Varian Medical Systems, Inc. provides cancer therapy systems worldwide. Its Oncology Systems segment designs, manufactures, sells, and services hardware and software products to treat cancer with radiation, including linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment, and accessories, as well as information management, treatment planning, and image processing software. This segment?s products enable oncology departments to perform conventional radiotherapy, intensity modulated radiation therapy, image guided radiation therapy, and stereotactic radiotherapy, as well as brachytherapy techniques. Oncology Systems segment markets its products to cancer treatment clinics, university research and community hospitals, private and governmental institutions, healthcare agencies, doctors? offices, and cancer care clinics. The company?s X-ray Products segment designs, manufactures, and markets X-ray imaging components and subsystems, such as X-ray tubes for computed tomography, scanning, radioscopic/fluoroscopic imaging, mammography, and special procedures and industrial applications; and flat panel detectors for filmless X-ray imaging. This segment sells its products to imaging system original equipment manufacturers. Varian Medical Systems also provides Linatron X-ray accelerators and IntellX imaging product for security and inspection purposes; designs, manufactures, and integrates products and systems for delivering proton therapy; and develops technologies in the areas of digital X-ray imaging technology, volumetric and functional imaging, improved X-ray sources, and technology for security and cargo screening applications. It has a strategic development agreement with Calypso Medical Technologies, Inc. to develop products integrating Calypso System with the company?s radiotherapy treatment technologies. The company, formerly known as Varian Associates, Inc., was founded in 1948 and is headquartered in Palo Alto, California.www.varian.com
5,100 Employees
Founded in 1948
Varian Medical Systems Inc. (VAR:NYSE)
LAST $45.61 USD
CHANGE TODAY -0.15 -0.33%
VOLUME 688.2K
As of 4:03 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Varian Medical Systems Inc. (VAR)
|
OPEN
$45.57
|
PREVIOUS CLOSE
$45.76
|
|
|
DAY HIGH
$45.79
|
DAY LOW
$45.39
|
|
|
52 WEEK HIGH
11/16/09 - $46.88
|
52 WEEK LOW
03/6/09 - $27.10
|
|
|
MARKET CAP
5.7B
|
AVERAGE VOLUME 3 mo
720.5K
|
|
|
DILUTED EPS TTM
$2.66
|
SHARES OUTSTANDING
125.5M
|
|
|
VAR Does Not Pay Dividends
|
P/E TTM
17.2x
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Marcial: A Fool's Rally?
04/20/2009 12:01 AM ET
Many pros think the market has already bottomed and have snapped up beaten-down big-cap stocks. But many of them are not willing to say the bear market is over
Why Elekta May Be A Stockholm Standout
08/06/2007 5:00 AM ET
Precision-Guided Cancer Weapons
02/12/2007 5:00 AM ET
Innovations in radiation therapy are reducing "collateral damage" and saving lives
Online Extra: Radiation Therapy: New Rays Of Hope
02/12/2007 5:00 AM ET
More than two-thirds of all cancer patients in the U.S. receive radiation treatments as part of their hospital care. New technology could greatly improve the prognosis
related news
Final Glance: Health Care Equipment companies
AP Digital - 11/20/2009 5:50 PM ET
Midday Glance: Health Care Equipment companies
AP Digital - 11/20/2009 1:02 PM ET
Early Glance: Health Care Equipment companies
AP Digital - 11/20/2009 10:32 AM ET
Final Glance: Health Care Equipment companies
AP Digital - 11/19/2009 5:47 PM ET
Early Glance: Health Care Equipment companies
AP Digital - 11/19/2009 10:47 AM ET
VAR Top Compensated Officers
Mr. Timothy E. Guertin
Chief Executive Officer, President and Execut...
Age: 60
Total Annual Compensation: $825.6K
Ms. Elisha W. Finney
Chief Financial Officer and Corporate Senior ...
Age: 47
Total Annual Compensation: $489.7K
Mr. Dow R. Wilson
Corporate Executive Vice President and Presid...
Age: 45
Total Annual Compensation: $894.6K
Mr. Robert H. Kluge
Corporate Senior Vice President and President...
Age: 63
Total Annual Compensation: $388.0K
Mr. John W. Kuo
Corporate Vice President, Corporate Secretary...
Age: 46
Total Annual Compensation: $341.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Varian Medical Systems Inc. (VAR)
Varian Medical Systems Inc. - Special/M&A Call
11/3/2009
Varian Medical Systems Inc. - Special/M&A Calls
Varian Medical Systems to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
10/30/2009
Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new treatments machines from Varian Medical Systems Inc. by the Instituto Portugues Oncologia, IPO Porto. The order, placed in August, includes the country's first Novalis Tx(TM) device for advanced radiosurgery and two Trilogy® medical linear accelerators offering RapidArc® radiotherapy capability. This new equipment will allow IPO to introduce new radiation delivery techniques that offer more efficient and more precise ways of treating cancer while reducing side effects.
Varian Medical Systems Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended Oct. 2, 2009; Provides Earnings Outlook for the First Quarter and Full Year of Fiscal 2010
10/29/2009
Varian Medical Systems Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended Oct. 2, 2009. For the quarter, the company reported operating earnings of $150.6 million, earnings from continuing operations before taxes of $150.4 million, earnings from continuing operations of $97.2 million or $0.78 per diluted share and net earnings of $97.0 million or $0.77 per diluted share on revenues of $642.0 million against operating earnings of $135.6 million, earnings from continuing operations before taxes of $137.8 million, earnings from continuing operations of $87.1 million or $0.68 per diluted share and net earnings of $78.5 million or $0.68 per diluted share on revenues of $592.7 million for the same period a year ago. For the full year, the company reported operating earnings of $474.1 million, earnings from continuing operations before taxes of $474.6 million, earnings from continuing operations of $331.5 million or $2.65 per diluted share and net earnings of $319.0 million or $2.55 per diluted share on revenues of $2,214.1 million against operating earnings of $419.4 million, earnings from continuing operations before taxes of $426.0 million, earnings from continuing operations of $295.3 million or $2.31 per diluted share and net earnings of $279.5 million or $2.19 per diluted share on revenues of $2,069.7 million for the same period a year ago. The sale of the non-proton therapy portion of the ACCEL business earlier in the year and its resulting classification as a discontinued operation reduced net earnings per diluted share by $0.01 to $0.77 for the quarter and by $0.10 to $2.55 for the fiscal year. The company believes that for the first quarter of fiscal year 2010, total company revenues could increase by 3 to 4% over the prior year. Including a higher tax rate and a one-time $0.02-per-share charge for a recently completed reduction in force, net earnings per diluted share from continuing operations for the first quarter could be in the range of $0.52 to $0.56. For the full fiscal year 2010, the company estimates that revenues and operating earnings could increase by 4 to 5% over the fiscal year 2009 total and that net earnings per diluted share from continuing operations could be in the range of $2.65 to $2.75.
VAR Competitors
| Company | Last | Change |
| Elekta AB | kr150.50 SEK | +2.75 |
| Hitachi Medical Corporation | ¥773.00 JPY | -1.00 |
| Hologic Inc | $14.39 USD | -0.68 |
| PerkinElmer Inc | $19.04 USD | -0.32 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | VAR | Industry Range |
| Price/Earnings | 17.2x |
|
| Price/Sales | 2.6x |
|
| Price/Book | 4.3x |
|
| Price/Cash Flow | 17.9x |
|
| TEV/Sales | 2.3x |
|
|
VAR |
||
|
VAR transactions
| Type Date |
Target |
|
Merger/Acquisition
June 25, 2009 |
IKOEmed, LLC |
More Recent News About Varian Medical Systems Inc.
More news for VAR
Varian Medical Systems sees rise in Q4 profit, revenue
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | view digital edition | ...Click here to read the whole Article (external link)
Varian Medical Systems, Inc. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
Varian Medical Systems, Inc. (VAR) F4Q09 Earnings Call October 29, 2009 5:00 pm ET Executives Spencer R. Sias – Vice President, Corporate Communications and Investor Relations Timothy E. Guertin – President and Chief Executive Officer Elisha W. Finney – Corporate Senior Vice President and Chief Financial Officer Analysts Amit Bhalla - Citi Amit Hazan – Oppenheimer Tycho Peterson - JP Morgan Dalton Chandler – Needham & Company Jeffrey D. Johnson - Robert W. Baird & Co. Junaid Husain - Soleil Securities Sean Lavin – Lazard Nathan Sadeghi – Highside Charley Jones – Barrington Research Associates Presentation Operator Welcome to the Fourth Quarter 2009 Varian Medical Systems Earnings Conference Call. At this time all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. (Operator's Instructions) As a reminder this conference is being recorded for replay purposes. I would now like to turn the conference over to your host for today, Mr. Spencer Sias, Vice President of Investor Relations and Corporate Communications. Spencer R. Sias Good afternoon and welcome to Varian Medical Systems conference call for the fourth quarter of fiscal year 2009. With me are Tim Guertin, President and CEO, Elisha Finney CFO, and Tai Chen, our Corporate Controller. Tim and Elisha will summarize our results and will take your questions following the presentation. To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and...Click here to read the whole Article (external link)
Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
PORTO, Portugal, Oct. 30 /PRNewswire-FirstCall/ -- Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new treatments machines from Varian Medical Systems (NYSE: VAR - News) by the Instituto Portugues Oncologia, IPO Porto. The order, placed in August, includes the country's first Novalis Tx(TM) device for advanced radiosurgery and two Trilogy® medical linear accelerators offering RapidArc® radiotherapy capability. The project involves complete reconstruction of an institute that first began treating cancer patients in 1974 and has offered top quality cancer care for north Portugal's 3.6m inhabitants since. Four Clinac® DHX linear accelerators, ARIA(TM) oncology information software with 64 workstations and 15 treatment planning systems also form part of the largest single radiotherapy order ever placed in Portugal. Varian has also signed an eight-year service contract with the institute."The efficacy of radiotherapy treatments is already very well known but the improvement in quality that will come from this project will be of enormous benefit to the quality of life of patients in the north of Portugal," said Helena Pereira, M.D., IPO's radio oncology service medical director. "This new equipment will allow us to introduce new radiation delivery techniques that offer more efficient and more precise ways of treating cancer while reducing side effects."Laranja Pontes, M.D., the Institute's CEO, added, "We have been working with Varian for twenty ye...Click here to read the whole Article (external link)
Varian Medical 4Q profit rises on system sales
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Scientific Presentations at 2009 ASTRO Meeting Highlight RapidArc(R) Radiotherapy Technology from Varian Medical Systems
CHICAGO, Nov. 10 /PRNewswire-FirstCall/ -- Clinicians using RapidArc® radiotherapy technology for fast, precise, non-invasive cancer treatments have found that they are able to substantially reduce scatter dose to surrounding healthy tissues, according to several presentations and posters presented this week at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago. With RapidArc, doctors were able to quickly administer image-guided radiotherapy or radiosurgery treatments using fewer monitor units, which translates to less total body irradiation during treatment. In addition, a number of planning studies documented the clinical advantages of RapidArc over other forms of intensity-modulated radiotherapy (IMRT). ASTRO is the largest association of radiation oncology professionals in the world, with 10,000 members, including radiation oncologists, radiation oncology nurses, medical physicists, radiation therapists, dosimetrists and biologists. The 2009 meeting was held in Chicago, Illinois, from November 1-5. Some of the highlights:PROSTATE CANCERIn the vast majority of cases, RapidArc treatments for prostate cancer result in equal or better tumor coverage with less dose to the bladder and rectum, compared to conventional fixed-field IMRT, according to a research team from the Finsen Centre(*) in Copenhagen, Denmark. The RapidArc treatments also use much fewer monitor units--a two to three-fold decrease--which means that less scattered, non-therapeutic radiation is delivered during these treatments, which took, on average, 1.25 minutes to deliver once patients were positioned for treatment.(1)These results were echoed by researchers at the University of Alabama, Birmingham (UAB(*)), who found that RapidArc is more efficient in terms of delivery time and the number of monitor units needed,...Click here to read the whole Article (external link)
Varian Medical upgraded by Soleil
DateResearch FirmActionFromTo2-Nov-09SoleilUpgradeHoldBuy15-Sep-09Barrington ResearchDowngradeOutperformMkt Perform21-Aug-09CitigroupUpgradeHoldBuy2-Jul-09SoleilDowngradeBuyHold23-Jun-09Robert W. BairdInitiatedNeutral13-Apr-09Barrington ResearchInitiatedOutperform5-Jan-09OppenheimerDowngradeOutperformPerform6-Oct-08JP MorganDowngradeOverweightNeutral11-Aug-08CitigroupDowngradeBuyHold10-Apr-08Lazard CapitalInitiatedBuy10-Mar-08Jefferies & CoDowngradeHoldUnderperform24-Jan-08Leerink SwannUpgradeMkt PerformOutperform2-Jan-08SoleilUpgradeHoldBuy11-Jun-07CIBC Wrld MktsUpgradeSector PerformSector Outperform26-Apr-07Jefferies & CoDowngradeBuyHold25-Jan-07Leerink SwannDowngradeOutperformMkt Perform10-Oct-06CitigroupInitiatedBuy6-Oct-06CIBC Wrld MktsInitiatedSector Perform21-Jun-06OppenheimerUpgradeNeutralBuy2-Feb-06OppenheimerDowngradeBuyNeutral14-Dec-05Banc of America SecInitiatedNeutral17-Nov-05Needham & CoInitiatedBuy19-Oct-05Jefferies & CoUpgradeHoldBuy18-Oct-05OppenheimerInitiatedBuy21-Sep-05Jefferies & CoDowngradeBuyHold25-Apr-05Hibernia Southcoast CapitalUpgradeHoldBuy6-Apr-05Jefferies & CoInitiatedBuy9-Mar-05Sun Trust Rbsn HumphreyUpgradeNeutralBuy13-Dec-04Hibernia Southcoast CapitalDowngradeBuyHold21-Jul-04KeyBanc Capital Mkts / McDonaldUpgradeHoldBuy...Click here to read the whole Article (external link)
Researchers from UC Irvine Medical Center Find Clinical Advantages to Using RapidArc(R) Radiotherapy for the Stereotactic Treatment of Tumors
PALO ALTO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Researchers from the University of California, Irvine Medical Center reported last week that image-guided RapidArc® radiotherapy from Varian Medical Systems (NYSE: VAR - News) has clinical advantages over earlier fixed-beam approaches to stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) for treating cancer. RapidArc, Varian's technology for delivering volumetric modulated arc therapy (VMAT), enables clinicians to deliver a highly-precise image-guided intensity-modulated treatment quickly, often with just one revolution of the treatment machine around the patient."We found that we can deliver RapidArc treatments much more quickly, with an average of 76% less 'beam on' time, and also using 31% fewer monitor units, which could limit unintended and undesired radiation exposure to patients," said Daniel C. Schiffner, M.D., chief resident in the UCI Department of Radiation Oncology, in a presentation at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago.(1)"The reduction in monitor units is important because it limits the degree to which patients are exposed to radiation leakage from the treatment machine," he said. "In addition, less 'beam on' time improves our clinical workflow, improves patient comfort during treatment, and limits the potential for patient and organ motion during the treatment session, which can allow more accurate dose targeting."In addition to being faster and requiring fewer monitor units, ...Click here to read the whole Article (external link)
VARIAN MEDICAL SYSTEMS INC Files SEC form 8-K, Other Events
Show all filings for VARIAN MEDICAL SYSTEMS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for VARIAN MEDICAL SYSTEMS INC 17-Nov-2009Other Events Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intende...Click here to read the whole Article (external link)
Advances in Radiation Therapy Enable Doctors to Improve the Quality of Treatments for Patients With Head and Neck Cancer
PALO ALTO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Clinical studies suggest that advanced treatments like intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) are enabling radiation oncologists to enhance post-treatment health-related quality of life for patients with head and neck cancer. In an educational session for radiotherapy professionals, delivered by two noted experts during the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago last week, Avraham Eisbruch, M.D., professor at the University of Michigan, discussed how careful implementation of IMRT in the treatment of head and neck cancer can achieve high tumor control rates while minimizing xerostomia, a dry mouth condition that occurs when salivary glands are damaged.Citing a new report summarizing results from RTOG 0022, a multi-institutional study comparing IMRT with earlier forms of treatment for head and neck cancer, Dr. Eisbruch said that IMRT for head and neck cancer achieved important goals in reducing treatment toxicity, notably xerostomia, and in yielding a high tumor control rate of 90%.(1)For patients enrolled in the study and treated with IMRT, only 55% experienced Grade 2 or worse xerostomia at six months after treatment, as compared with 84% of patients treated with earlier forms of radiotherapy -- a reduction of 35%. For the IMRT group, the percentage of patients with Grade 2 or worse xerostomia decreased steadily, to 25% at 12 months and 16% at 24 months. "This kind of improvement over time is not something we had been seeing with conventional forms of radiotherapy,(2)" said Dr. Eisbruch, who served as chair of RTOG 0022."Also, emerging data is suggesting that we can get improvements in broader aspects of post-treatment quality of life by using IMRT, beyond reducing xerostomia," Eisbruch said. "Sev...Click here to read the whole Article (external link)
Would you like to leave a comment about Varian Medical Systems Inc. VAR
Find out what social network information about Varian Medical Systems Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Varian Medical Systems Inc. there is more great information available at Realpennies.com